

**Information notice relating to
the conclusion of a related parties agreement
pursuant to Article L. 22-10-13 of the French Commercial Code**

**Agreement relating to the subscription of Company's shares with
warrants signed on May 2nd, 2025
between the Company and Samsara BioCapital, L.P.
(Authorisation granted by the Board of Directors on 02 May 2025)**

Daix, 7 May 2025 - Pursuant to Articles L. 22-10-13 and R 22-10-17 of the French Commercial Code, Inventiva S.A. (the 'Company') announces that on 2 May 2025, Company signed a share subscription agreement with Samsara BioCapital, L.P. ('Samsara').

Purpose: The Company signed this subscription agreement with Samsara on the occasion of the issuance of the second tranche of the structured financing issued on October 14th, 2024. As Mr. Srinivas AKKARAJU is a member of the Company's Board of Directors and one of Samsara's senior executives, the subscription agreement for Company's shares with warrants constitutes a related-parties agreement under Article L. 225-38 et seq. of the French Commercial Code.

Financial terms: In consideration for the payment of €8,959,999.95 Samsara has subscribed to 6,637,037 shares with share warrants giving the right to subscribe to a further 5,973,333 shares when the third tranche of the structured financing will be issued.

Interested party: Mr Srinivas AKKARAJU, a director of the Company, is an officer of Samsara BioCapital GP, LLC. Samsara BioCapital GP, LLC is the general partner of Samsara BioCapital L.P. Samsara BioCapital L.P. has signed the subscription agreement for 6,637,037 Company's shares with share warrants.

Reasons why it is in the Company's interest to enter into this subscription agreement: The subscription agreement with Samsara has been entered into because it is in the Company's interest to successfully raise the second tranche of the financing announced on 14 October 2024 for the continued clinical development of lanifibranor, the production of a drug containing the lanifibranor molecule and the commercial launch of this drug.

Approval of the agreement: The Company's Board of Directors authorised the conclusion of the agreement during its May 2nd, 2025 meeting, in compliance with Article L. 225-38 of the French Commercial Code; Mr Srinivas AKKARAJU did not take part in the deliberations or vote. The agreement will be submitted for approval to the Company's General Meeting of Shareholders called in 2026 to approve the financial statements for the current financial year.

* * *